Immune to Cancer: The CRI Blog
-
#AACR16 Update: Checkpoint Inhibition and Improving Anti-Tumor Immunity
Releasing the brakes on the immune system to overcome cancer
-
Oncogene Initiates Cancer Development through Immune Checkpoints
CLIP investigator Dean W. Felsher, MD, PhD, published his findings in the journal Science.
-
Jimmy Carter to Receive Immunotherapy for Melanoma
The former president will receive a drug called pembrolizumab, a PD-1-blocking antibody.
-
European Regulators Approve Pembrolizumab (Keytruda) as First-line Treatment of Advanced Melanoma
The decision makes pembrolizumab the second PD-1-blocking drug to receive approval in Europe.
-
Phase 3 Trial Shows Nivolumab Improves Survival in Advanced Kidney Cancer
The trial ended early because data showed that patients lived longer on nivolumab compared to the standard-of-care…
-
New Clinical Trials to Offer Immunotherapy as Frontline Treatment for Lung Cancer
Patients with lung cancer will soon be able to receive immunotherapy as first-line treatment on an experimental…
-
Merck’s PD-1 Drug Outperforms Ipilimumab for Treatment of Advanced Melanoma
Data from a phase III trial indicate that Keytruda stands ready to become standard-of-care for advanced melanoma.
-
What Cancer Patients Need to Know About the Opdivo Approval
Now that Opdivo (nivolumab) has been FDA approved for two cancer types, many patients are wondering: what’s…
-
Big News: FDA Approves Opdivo (Nivolumab) for Lung Cancer
The PD-1 checkpoint inhibitor Opdivo® (nivolumab) is a new treatment option for patients with non-small cell lung…